Companies Choose ALPHADAS®, Logos Technologies Early Phase EDC System
Richmond Pharmacology, Community Research, and Fundación de Investigación de Diego, Puerto Rico has selected the ALPHADAS' early phase, e-source data capture system and site automation software suite which gives clinical research sites tools to accelerate and streamline their clinical trial operations and service. ALPHADAS is to be implemented initially in Richmond Pharmacology's MHRA Phase I Accredited facility, located in MayDay Hospital, London, UK as well as in Community Research's research facility, located in Cincinnati, Ohio, USA. ALPHADAS will be used in Fundación's new, purpose built 20,000 sq ft, research facility, located in San Juan, Puerto Rico. Fundacion de Investigacion new facility includes a 30 bed phase 1 unit, expanded ambulatory clinical trials space, and a bio-analytical laboratory.
ALPHADAS, is an e-Source, pro-active EDC system designed specifically for early phase clinical trials. Logos Technologies continues to invest in ALPHADAS, increasing its performance and functionality.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
